Predicting subsite interactions of plasmin with substrates and inhibitors through computational docking analysis

References

• Petersen TE, Martzen MR, Ichinose A, Davie EW. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 1990;265:6104–6111.
   PubMedGoogle Scholar
• Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967;242:2333–2342.
   PubMed Web of Science ®Google Scholar
• Okada Y, Tsuda Y, Tada M, Wanaka K, Okamoto U, Hijikata-Okunomiya A et al. Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship. Chem Pharm Bull 2000;48:1964–1972.
   PubMedGoogle Scholar
• Tsuda Y, Tada M, Wanaka K, Okamoto U, Hijikata-Okunomiya A, Okamoto S et al. Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors. Chem Pharm Bull 2001;49:1457–1463.
   PubMedGoogle Scholar
• Xue F, Seto CT. Structure-activity studies of cyclic ketone inhibitors of the serine protease plasmin: design, synthesis, and biological activity. Bioorg Med Chem 2006;14:8467–8487.
   PubMedGoogle Scholar
• Okamoto S, Hijikata-Okunomiya A, Wanaka K, Okada Y, Okamoto U. Enzyme-controlling medicines: introduction. Semin Thromb Hemost 1997;23:493–501.
   PubMedGoogle Scholar
• Judex MO, Mueller BM. Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more. Am J Pathol 2005;166:645–647.
   PubMedGoogle Scholar
• Kido H, Okumura Y, Yamada H, Le TQ, Yano M. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr Pharm Des 2007;13:405–414.
   PubMedGoogle Scholar
• Parry MA, Fernandez-Catalan C, Bergner A, Huber R, Hopfner KP, Schlott B et al. The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action. Nat Struct Biol 1998;5:917–923.
   PubMedGoogle Scholar
• Wanaka K, Okada Y, Tsuda Y, Okamoto U, Hijikata-Okunomiya A, Okamoto S. Synthesis of trans-4-aminomethylcyclohexanecarbonyl-L- and -D-phenylalanine-4-carboxymethylanilide and examination of their inhibitory activity against plasma kallikrein. Chem Pharm Bull 1992;40:1814–1817.
   PubMedGoogle Scholar
• McGrath ME, Sprengeler PA, Hirschbein B, Somoza JR, Lehoux I, Janc JW et al. Structure-guided design of peptide-based tryptase inhibitors. Biochemistry 2006;45:5964–5973.
   PubMedGoogle Scholar
• Wang X, Lin X, Loy JA, Tang J, Zhang XC. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science 1998;281:1662–1665.
   PubMed Web of Science ®Google Scholar
• Hajduk PJ, Boyd S, Nettesheim D, Nienaber V, Severin J, Smith R et al. Identification of novel inhibitors of urokinase via NMR-based screening. J Med Chem 2000;43:3862–3866.
   PubMedGoogle Scholar
• Case DA, Darden TA, Cheatham TE, III Simmerling, CL, Wang J, Duke RE, Luo R, Crowley M, Walker RC, Zhang W, Merz KM, Wang B, Hayik S, Roitberg A, Seabra G, Kolossváry I, Wong KF, Paesani F, Vanicek J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, Yang L, Tan C, Mongan J, Hornak V, Cui G, Mathews DH, Seetin MG, Sagui C, Babin V, Kollman PA. AMBER 10, University of California, San Francisco, 2008.
   Google Scholar
• Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 2003;24:1999–2012.
   PubMed Web of Science ®Google Scholar
• Boström J, Greenwood JR, Gottfries J. Assessing the performance of OMEGA with respect to retrieving bioactive conformations. J Mol Graph Model 2003;21:449–462.
   PubMed Web of Science ®Google Scholar
• McGann MR, Almond HR, Nicholls A, Grant JA, Brown FK. Gaussian docking functions. Biopolymers 2003;68:76–90.
   PubMed Web of Science ®Google Scholar
• Grant JA, Pickup BT, Nicholls A. A smooth permittivity function for Poisson-Boltzmann solvation methods. J Comp Chem 2001;22:608–640.
   Web of Science ®Google Scholar
• Tomoo K, Satoh K, Tsuda Y, Wanaka K, Okamoto S, Hijikata-Okunomiya A et al. Binding diversity of a noncovalent-type low-molecular-weight serine protease inhibitor and function of a catalytic water molecule: X-ray crystal structure of PKSI-527-inhibited trypsin. J Biochem 2001;129:455–460.
   PubMedGoogle Scholar
• Okada Y, Tsuda Y, Teno N, Wanaka K, Sasaki K, Hijikata A et al. Synthesis of plasmin substrates and relationship between their structure and plasmin activity. Int J Pept Protein Res 1986;27:79–85.
   PubMedGoogle Scholar
• Tsuda Y, Teno N, Okada Y, Wanaka K, Bohgaki M, Hijikata-Okunomiya A et al. Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikrein. Chem Pharm Bull 1989;37:3108–3111.
   PubMedGoogle Scholar
• Straub A, Roehrig S, Hillisch A. Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban). Curr Top Med Chem 2010;10:257–269.
   PubMedGoogle Scholar
• Teno N, Wanaka K, Okada Y, Taguchi H, Okamoto U, Hijikata-Okunomiya A et al. Development of active center-directed plasmin and plasma kallikrein inhibitors and studies on the structure-inhibitory activity relationship. Chem Pharm Bull 1993;41:1079–1090.
   PubMedGoogle Scholar
• Tada M. Development of plasmin and plasma kallikrein inhibitors, and development of purification method for plasma kallikrein. Thesis of Kobe Gakuin University, 2002.
   Google Scholar
• Nienaber VL, Davidson D, Edalji R, Giranda VL, Klinghofer V, Henkin J et al. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Structure 2000;8:553–563.
   PubMed Web of Science ®Google Scholar